Literature DB >> 12233982

Clinical uses of naltrexone: a review of the evidence.

Vania Modesto-Lowe1, Jeffrey Van Kirk.   

Abstract

The implication of the opioidergic system in the pathogenesis of various substance use disorders has led to renewed interest in expanding the clinical uses of naltrexone, an opioid antagonist. This article examines the evidence for the efficacy of naltrexone in a variety of substance use and psychiatric disorders. Naltrexone can be an effective treatment for alcohol and opioid dependence if issues of compliance are adequately addressed. Thus far, no definitive role has been found for naltrexone in the treatment of other psychiatric disorders. Further research needs to be done in self-injurious behavior, gambling, cocaine, and nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12233982     DOI: 10.1037//1064-1297.10.3.213

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  15 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

Review 2.  Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addiction.

Authors:  Natalie A Hadad; Lori A Knackstedt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-06       Impact factor: 4.530

Review 3.  Effect of opioid antagonists on sex hormone secretion.

Authors:  H Tenhola; D Sinclair; H Alho; T Lahti
Journal:  J Endocrinol Invest       Date:  2011-12-15       Impact factor: 4.256

Review 4.  Conceptualizing the neurobiology of non-suicidal self-injury from the perspective of the Research Domain Criteria Project.

Authors:  Melinda Westlund Schreiner; Bonnie Klimes-Dougan; Erin D Begnel; Kathryn R Cullen
Journal:  Neurosci Biobehav Rev       Date:  2015-09-28       Impact factor: 8.989

5.  Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.

Authors:  Jeffrey J Everly; Anthony DeFulio; Mikhail N Koffarnus; Jeannie-Marie S Leoutsakos; Wendy D Donlin; Will M Aklin; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2011-05-03       Impact factor: 6.526

6.  Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.

Authors:  Anthony DeFulio; Jeffrey J Everly; Jeannie-Marie S Leoutsakos; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2011-07-22       Impact factor: 4.492

7.  Naltrexone treatment reverses astrocyte atrophy and immune dysfunction in self-harming macaques.

Authors:  Kim M Lee; Kevin B Chiu; Peter J Didier; Kate C Baker; Andrew G MacLean
Journal:  Brain Behav Immun       Date:  2015-07-17       Impact factor: 7.217

Review 8.  Agents in development for the management of cocaine abuse.

Authors:  David A Gorelick; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  A placebo-controlled trial of modafinil for nicotine dependence.

Authors:  Robert A Schnoll; E Paul Wileyto; Angela Pinto; Frank Leone; Peter Gariti; Steven Siegel; Kenneth A Perkins; Charles Dackis; Daniel F Heitjan; Wade Berrettini; Caryn Lerman
Journal:  Drug Alcohol Depend       Date:  2008-06-09       Impact factor: 4.492

10.  Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence.

Authors:  Jesse J Suh; Helen M Pettinati; Kyle M Kampman; Charles P O'Brien
Journal:  Am J Addict       Date:  2008 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.